key: cord-0737052-j95sfxn1 authors: Gagne, Matthew; Corbett, Kizzmekia S.; Flynn, Barbara J.; Foulds, Kathryn E.; Wagner, Danielle A.; Andrew, Shayne F.; Todd, John-Paul M.; Honeycutt, Christopher Cole; McCormick, Lauren; Nurmukhambetova, Saule T.; Davis-Gardner, Meredith E.; Pessaint, Laurent; Bock, Kevin W.; Nagata, Bianca M.; Minai, Mahnaz; Werner, Anne P.; Moliva, Juan I.; Tucker, Courtney; Lorang, Cynthia G.; Zhao, Bingchun; McCarthy, Elizabeth; Cook, Anthony; Dodson, Alan; Teng, I-Ting; Mudvari, Prakriti; Roberts-Torres, Jesmine; Laboune, Farida; Wang, Lingshu; Goode, Adrienne; Kar, Swagata; Boyoglu-Barnum, Seyhan; Yang, Eun Sung; Shi, Wei; Ploquin, Aurélie; Doria-Rose, Nicole; Carfi, Andrea; Mascola, John R.; Boritz, Eli A.; Edwards, Darin K.; Andersen, Hanne; Lewis, Mark G.; Suthar, Mehul S.; Graham, Barney S.; Roederer, Mario; Moore, Ian N.; Nason, Martha C.; Sullivan, Nancy J.; Douek, Daniel C.; Seder, Robert A. title: Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques is coincident with anamnestic antibody response in the lung date: 2021-12-03 journal: Cell DOI: 10.1016/j.cell.2021.12.002 sha: beef518b0f01ae153e754d34a4c53aa0e35e4bc0 doc_id: 737052 cord_uid: j95sfxn1 mRNA-1273 vaccine efficacy against SARS-CoV-2 Delta wanes over time; however, there are limited data on the impact of durability of immune responses on protection. Here, we immunized rhesus macaques and assessed immune responses over one year in blood, upper and lower airways. Serum neutralizing titers to Delta were 280 and 34 reciprocal ID50 at weeks 6 (peak) and 48 (challenge), respectively. Antibody binding titers also decreased in bronchoalveolar lavage (BAL). Four days after Delta challenge, virus was unculturable in BAL and subgenomic RNA declined by ∼3-log10 compared to control animals. In nasal swabs, sgRNA was reduced by 1-log10 and virus remained culturable. Anamnestic antibodies (590-fold increased titer) but not T cell responses were detected in BAL by day 4 post-challenge. mRNA-1273-mediated protection in the lungs is durable but delayed and potentially dependent on anamnestic antibody responses. Rapid and sustained protection in upper and lower airways may eventually require a boost. increased 37000-fold relative to week 48 after immunization, from ~870 to ~3.2x10 7 AUC, and 307 was higher than WA1 GMT. In contrast, B.1.617.2 GMT in the mRNA-1273 group had 308 increased only 475-fold during that time span, from ~1.2x10 9 AUC to ~5.7x10 11 AUC, and was 309 equivalent to WA1 GMT at day 14. In addition, WA1 S-2P binding GMT in control NHP 310 increased 39-fold from ~0.9 BAU/mL to ~35 BAU/mL between week 48 after immunization and 311 day 14 after challenge while GMT in vaccinated NHP rose 5-fold from ~189 to ~1030 BAU/mL 312 (Fig. 1A) . Pseudovirus neutralizing responses were also measured to D614G and B.1.617.2 at days 2, 4, 7 315 and 14. The hierarchy of neutralizing antibody titers elicited by the vaccine remained stable until 316 day 14, when titers to B.1.617.2 approached those of D614G (P>0.05) (Fig. 1F ). These findings 317 show that while serum antibody responses did not increase at a faster rate in vaccinated NHP 318 than in controls, they were boosted by infection. Fig S2) . Last, we did not 332 detect differential IgA responses or ACE2 binding inhibition between vaccinated animals or 333 controls in either the lower or upper airway (Fig. 3E-H and Fig S2) . These data show that the 334 mRNA-1273-vaccinated NHP made an anamnestic IgG response in the lower airways. 335 336 J o u r n a l P r e -p r o o f Although the total IgG concentration in the lungs of both vaccinated and unvaccinated NHP 337 increased following challenge, this increase was greater in the control cohort. Geometric mean 338 IgG concentrations in the vaccinated animals rose from 8.3 µg/mL at week 42 after 339 immunization to 11.2 and 24.2 µg/mL on days 2 and 4 after challenge, respectively. 340 Simultaneously, IgG concentrations in the controls rose from a baseline of 11 µg/mL to 16.2 and 341 73.9 µg/mL on days 2 and 4 (Fig. S7A ). This rapid response after challenge is consistent with 342 our prior experience of a protein SARS-CoV-2 vaccine in which we observed a rapid increase in 343 both total IgG and measles morbillivirus (MeV) titers in primates that had also been vaccinated 344 against MeV (Francica et al., 2021) . In the present study, although binding titers were similar 345 between both cohorts prior to challenge, responses to MeV increased more rapidly in the control 346 group. GMT to MeV in the lower airway of vaccinated NHP increased from 14 units/mL (U/mL) 347 at week 42 after immunization to 20 U/mL on day 4 after challenge, while GMT in control NHP 348 increased from 12 to 67 U/mL at the same timepoints (Fig. S7B) . 349 An anamnestic S-specific B cell response in the lower airways would likely be the underlying 351 mechanism for an increase in local antibody titers. While we were unable to collect a sufficient 352 number of B cells in BAL to analyze after B.1.617.2 challenge, we were nevertheless able to 353 interrogate these cells in blood. Memory B cells which bound both WA1 S-2P and B.1.617.2 S-354 2P dominated the S-specific immune response of vaccinated NHP. While the total frequency of 355 all S-binding memory B cells increased, the proportion of these dual-specific cells remained 356 between 85-90% (Fig. 4E ). In contrast, B.1.617.2 challenge in control NHP elicited a higher 357 frequency of memory B cells specific only for B.1.617.2 S, with a geometric mean frequency of 358 57% at day 28 ( Fig 4E) . 72% of S-binding B cells in control NHP had a phenotype consistent 359 J o u r n a l P r e -p r o o f with activated memory B cells, in contrast to the vaccinated cohort in which 49% of cells had an 360 activated memory phenotype and 38% of cells had a resting memory phenotype (Fig. 4F) . 361 362 T cell responses in blood and BAL following vaccination and B.1.617.2 challenge 363 After showing a potential role for memory B cell responses in controlling virus replication in 364 lower airways, we also measured T cell responses to SARS-CoV-2 S in the blood and BAL 365 following challenge. By day 7, TH1 responses were elevated as compared to week 42 in both 366 compartments (Serum: P=0.0199; BAL: P=0.0097). However, the range of S-specific TH1 CD4 + 367 T cell frequencies in the BAL of control and vaccinated NHP overlapped (Fig. 5A , F). While we 368 observed increased IL-21 + TFH responses in vaccinated NHP by day 7 (P=0.0061) (Fig. 5E ), we 369 did not detect any TH2 responses following challenge in vaccinated or control animals (P>0.05) 370 ( Fig. 5B, G) . In contrast to the minimal vaccine-elicited CD8 + T cells prior to challenge, both 371 control and vaccinated NHP mounted CD8 + T cell responses following challenge (Fig. 5C, H) . 372 Finally, TH1 and CD8 + responses in the lungs to SARS-CoV-2 N, which was not encoded by 373 mRNA-1273, were only present in control NHP (Fig. S4 ). Together, these data demonstrate that 374 vaccination with mRNA-1273 not only elicited B and T cellular responses to SARS-CoV-2 S 375 following challenge but also protected NHP from encountering sufficient levels of SARS-CoV-2 376 N to mount a primary response to that antigen. showing that subcutaneous vaccines elicit antibodies that are detectable in the nose for at least 6 420 months (Clements and Murphy, 1986). The differential kinetics for the stability of IgG responses 421 in the upper respiratory and lower respiratory tract suggest unique mechanisms of turnover 422 within these different anatomical sites. the pre-challenge timepoint, and there was no detectable sgRNA_E in 6/8 vaccinated NHP by 432 day 7. This suggests that protection in the lower airway is durable but somewhat delayed and 433 may be dependent on a recall antibody response. It is also notable that while we were able to 434 detect binding and some functional antibodies in the blood and mucosa through the S-2P-ACE2 435 inhibition assay at time of challenge, neutralizing titers to B.1.617.2 were low to undetectable. Here we show that S-specific T cells decreased over the course of one year but were still 478 detectable in a subset of vaccinated NHP at the time of challenge. A second potential role for T 479 cells would be mediating control of viral replication in the lower airway to limit severe disease. 480 Notably, we did not see increased TH1 or CD8 + T cell responses in the BAL of vaccinated NHP 481 compared to controls following challenge. Interestingly, we detected CD8 + T cells in the blood 482 before detection in the lungs post-challenge, which requires further investigation. Formal We would like to thank G. Alvarado for experimental organization and administrative support. 516 The VRC Production Program (VPP) provided the WA1 protein for the avidity assay. We would 517 also like to especially thank A. See also Figure S1 and Table S1 . See also Figure S2 and Table S1 . See also Figure S3 and Table S1 . post-challenge. Lymphocytes in the BAL were stimulated with S1 and S2 peptide pools and 668 responses measured by intracellular cytokine staining using TH1 (F), TH2 (G), and CD8 markers 669 (H). Samples from weeks 6 and 25 were only stimulated with S1 peptides. were selected based on expression of CCR7 and CD45RA. Finally, SARS-CoV-2 S-specific 753 memory CD8 + T cells were gated according to co-expression of CD69 and IL-2, TNF or IFNγ. 754 The CD4 + events were defined as naïve, total memory or central memory according to 755 expression of CCR7 and CD45RA. CD4 + cells with a TH1 phenotype were defined as memory 756 cells that co-expressed CD69 and IL-2, TNF or IFNγ. CD4 + cells with a TH2 phenotype were 757 defined as memory cells that co-expressed CD69 and IL-4 or IL-13. TFH cells were defined as 758 central memory CD4 + T cells that expressed CXCR5, ICOS and PD-1. TFH cells were further 759 characterized as IL-21 + , CD69 + or CD40L + , CD69 + . 760 J o u r n a l P r e -p r o o f This study did not generate new unique reagents. 807 808 Data and code availability 809  All data reported in this paper will be shared by the lead contact upon request. Table S1 ) at a concentration of 0.18μg/mL in 1% 886 BSA/PBS for 1 hour at RT. After washing plates, serial dilutions of BAL fluid and nasal washes 887 in 1% BSA and 0.05% Tween-20 (1x PBS) were added for 1 hour at RT. Plates were then 888 washed 5 times and either 1μg/mL anti-human IgG sulfo-tag or 2μg/mL anti-human/NHP IgA Post-challenge Post-challenge References 1083 Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge. 1085 Efficacy and Safety of the mRNA-1273 SARS-CoV-2 1088 Vaccine SARS-CoV-2 neutralizing antibody 1091 structures inform therapeutic strategies Durable Humoral and Cellular Immune Responses 8 1094 Months after Ad26.COV2.S Vaccination Covid-19 Breakthrough Infections in Vaccinated 1097 Health Care Workers TLR3 and TLR7 RNA Sensor Activation during SARS-1100 CoV-2 Infection Effectiveness of mRNA-1273 against Delta, Mu, and other 1103 emerging variants. medRxiv Significant reduction in humoral immunity among 1106 healthcare workers and nursing home residents 6 months after COVID-19 BNT162b2 mRNA 1107 vaccination. medRxiv Waning of BNT162b2 Vaccine 1110 Protection against SARS-CoV-2 Infection in Qatar SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R Serum Neutralizing Activity of mRNA-1273 Against SARS-1116 CoV-2 Variants Development and persistence of local and systemic 1118 antibody responses in adults given live attenuated or inactivated influenza A virus vaccine Evaluation of the mRNA-1273 Vaccine against 1122 SARS-CoV-2 in Nonhuman Primates Protection against SARS-CoV-2 beta variant in 1125 mRNA-1273 vaccine-boosted nonhuman primates Immune correlates of protection by mRNA-1273 vaccine 1128 against SARS-CoV-2 in nonhuman primates mRNA-1273 protects against SARS-CoV-2 beta infection in 1131 nonhuman primates Immunological memory to SARS-CoV-2 assessed for up to 8 months 1134 after infection COVID-19 vaccine mRNA-1273 elicits a protective 1137 immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 1138 challenge OMIP-052: An 18-Color Panel for 1140 Measuring Th1, Th2, Th17, and Tfh Responses in Rhesus Macaques Antibody Persistence 1143 through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 Infection-and vaccine-induced 1147 antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant Infection and Vaccine-Induced 1151 Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants Protective antibodies elicited by SARS-CoV-2 spike 1154 protein vaccination are boosted in the lung after challenge in nonhuman primates SARS-CoV-2 mucosal antibody 1158 development and persistence and their relation to viral load and COVID-19 symptoms Evolution of antibody immunity to SARS-1162 CoV-2 SARS-CoV-2 variants of 1165 concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and 1166 vaccinees Immune correlates analysis of the 1169 mRNA-1273 COVID-19 vaccine efficacy clinical trial Distinct antibody and memory B cell 1172 responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination mRNA vaccines induce durable 1176 immune memory to SARS-CoV-2 and variants of concern Waning Immunity after the BNT162b2 Vaccine 1179 in Israel Longitudinal Study 1182 after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced 1183 Viral Variant Escape over Time. medRxiv Defining variant-resistant epitopes targeted by SARS-1186 CoV-2 antibodies: A global consortium study Broadly neutralizing antibodies to SARS-related viruses can be 1189 readily induced in rhesus macaques. bioRxiv Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets 1192 of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides The neutralizing antibody protects against SARS-CoV-2 infection in nonhuman primates Viridot: An automated virus 1199 plaque (immunofocus) counter for the measurement of serological neutralizing responses with 1200 application to dengue virus Neutralizing antibody levels are highly 1203 predictive of immune protection from symptomatic SARS-CoV-2 infection Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody 1208 Generation Waning Immune Humoral Response to BNT162b2 Covid-19 1211 Vaccine over 6 Months In vitro and in vivo functions of SARS-CoV-2 infection-1214 enhancing and neutralizing antibodies The SARS-CoV-2 Delta variant is poised to acquire complete 1217 resistance to wild-type spike vaccines. bioRxiv Effectiveness of Covid-19 Vaccines against the 1220 B.1.617.2 (Delta) Variant Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine 1223 against the B.1.351 Variant Single-shot Ad26 vaccine protects against SARS-1226 CoV-2 in rhesus macaques Changing composition of SARS-CoV-2 lineages 1229 and rise of Delta variant in England SARS-CoV-2 B.1.617.2 Delta variant replication and immune 1232 evasion Efficient transfer, 1234 integration, and sustained long-term expression of the transgene in adult rat brains injected 1235 with a lentiviral vector Clinical and virological features of SARS-CoV-2 variants of concern: a 1238 retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta) SARS-CoV-2 D614G spike mutation increases entry efficiency with 1242 enhanced ACE2-binding affinity Rapid induction of antigen-specific CD4(+) T 1245 cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA 1246 vaccination Nucleoside-modified mRNA vaccines induce 1249 potent T follicular helper and germinal center B cell responses Effectiveness of mRNA Covid-19 1252 Vaccine among U.S. Health Care Personnel Cross-neutralization of SARS-CoV-2 by a human 1255 monoclonal SARS-CoV antibody Reduced sensitivity of SARS-CoV-2 variant 1258 Delta to antibody neutralization Safety and Efficacy of the BNT162b2 mRNA 1261 Covid-19 Vaccine SARS-CoV-2 infection generates tissue-localized 1264 immunological memory in humans Comparison of two highly-effective mRNA 1267 vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv Safety and immunogenicity of 1271 ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults 1272 (COV002): a single-blind, randomised, controlled, phase 2/3 trial Role of IgA versus IgG in the 1274 control of influenza viral infection in the murine respiratory tract Functional SARS-CoV-2-1277 Specific Immune Memory Persists after Mild COVID-19 SARS-CoV-2 binding 1280 and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in 1281 rhesus macaques Safety and Efficacy of Single-Dose 1284 S Vaccine against Covid-19 Neutralizing antibody vaccine for pandemic and pre-emergent 1287 coronaviruses A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 Efficacy of NVX-CoV2373 Covid-19 Vaccine against the 1293 B.1.351 Variant Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector 1296 Vaccine against SARS-CoV-2 Variants. bioRxiv COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar SARS-CoV-2 mRNA vaccines induce persistent human 1302 germinal centre responses ChAdOx1 nCoV-1305 19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques Development of a Rapid Focus 1308 Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies CCR2 Signaling Restricts SARS-CoV-2 Infection. 1312 mBio Airborne transmission of respiratory viruses Ultrapotent antibodies against diverse and highly transmissible 1317 SARS-CoV-2 variants Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms 1320 and the ability to use ACE2 receptors from additional species Naturally enhanced neutralizing breadth 1323 against SARS-CoV-2 one year after infection mRNA vaccine-elicited antibodies to 1326 SARS-CoV-2 and circulating variants SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border 1329 transmission of high risk variants into the United Kingdom Human neutralizing antibodies against SARS-CoV-2 require intact Fc 1332 effector functions for optimal therapeutic protection Virological assessment of hospitalized patients 1335 with COVID-2019 Serum Neutralizing Activity Elicited by 1338 mRNA-1273 Vaccine FRNT assays were performed as previously described (Vanderheiden et al., 2020) . Briefly, 907 samples were diluted 3-fold in 8 serial dilutions using DMEM (VWR, #45000-304) in duplicates 908with an initial dilution of 1:10 in a total volume of 60l. Serially diluted samples were incubated 909with an equal volume of SARS-CoV-2 (100-200 foci per well) at 37ºC for 1 hour in a round-910 bottomed 96-well culture plate. The antibody-virus mixture was then added to Vero cells and 911 incubated at 37ºC for 1 hour. Post-incubation, the antibody-virus mixture was removed and 912 100µl of prewarmed 0.85% methylcellulose (Sigma-Aldrich, #M0512-250G) overlay was added 913 to each well. Plates were incubated at 37ºC for 24 hours. After 24 hours, methylcellulose overlay 914 J o u r n a l P r e -p r o o f minutes. Cells were incubated with an anti-SARS-CoV-2 S primary antibody directly conjugated 919 to biotin (CR3022-biotin) for 1 hour at room temperature. Next, the cells were washed three 920 times in PBS and avidin-HRP was added for 1 hour at room temperature followed by three 921 washes in PBS. Foci were visualized using TrueBlue HRP substrate (KPL, # 5510-0050) and 922 imaged on an ELISPOT reader (CTL). 923 924 Antibody neutralization was quantified by counting the number of foci for each sample using the 925 Viridot program (Katzelnick et al., 2018) . The neutralization titers were calculated as follows: 1 -926 (ratio of the mean number of foci in the presence of sera and foci at the highest dilution of 927 respective sera sample). Each specimen was tested in duplicate. The FRNT50 titers were 928 interpolated using a 4-parameter nonlinear regression in GraphPad Prism 8.4.3. Samples that did 929 not neutralize at the limit of detection at 50% were plotted at 15, which was used for geometric 930 mean calculations. 931 932 Pseudotyped lentiviral reporter viruses were produced as previously described (Wu et al., 2021) . Previously isolated and cryopreserved PBMC were centrifuged into warm RPMI/10% FBS and 985 resuspended in wash buffer (4% heat inactivated newborn calf serum/0.02% NaN3/ phenol-free 986 RPMI). PBMC were transferred to 96-wells, washed twice in 1X PBS and incubated with Aqua 987Blue live/dead cell stain (Thermo Fisher Scientific) at room temperature for 20 minutes.